PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer
- 9 March 2008
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 113 (3), 509-517
- https://doi.org/10.1007/s10549-008-9953-0
Abstract
Purpose To determine if response to endocrine therapy of breast cancer can be predicted by either a metabolic “flare reaction” detected by positron emission tomography (PET) with 2-[18F]-fluoro-2-deoxyglucose (FDG), induced by an estradiol challenge, or by estrogen-receptor (ER) status, determined by PET with the estrogen analog 16α-[18F]fluoroestradiol-17β (FES). Methods Fifty-one post-menopausal women with advanced estrogen-receptor positive breast cancer were studied. Patients underwent FES-PET and FDG-PET at baseline and repeat FDG-PET after 30 mg estradiol. Tracer uptakes was measured as the standardized uptake value (SUV). Patients were subsequently treated with either an aromatase inhibitor or fulvestrant. A prospectively defined cut-off SUV ≥ 2 for FES was considered positive for ER expression. A cutoff of ≥12% increase in SUV for FDG, determined by ROC analysis, represented metabolic flare. PET results were correlated with responsiveness to endocrine therapy. Results Seventeen patients responded and 34 patients did not respond to endocrine therapy. Four responders and one non-responder had a clinical flare reaction, while only the responders demonstrated metabolic flare. After estradiol challenge, a significantly higher mean (±SD) percent change in SUV for FDG was noted in responders (20.9 ± 24.2) compared with non-responders (−4.3 ± 11.0, P < 0.0001). On FES-PET, a higher tumor SUV was noted in responders (3.5 ± 2.5) compared with non-responders (2.1 ± 1.8, P = 0.0049). There was significantly longer overall survival in patients with metabolic flare than in those without flare regardless of type of endocrine therapy (P = 0.0062). Conclusion Baseline tumor FES uptake and metabolic flare after an estradiol challenge are both predictive of responsiveness to endocrine therapy in ER+ breast cancer.Keywords
This publication has 35 references indexed in Scilit:
- Concordance among Gene-Expression–Based Predictors for Breast CancerNew England Journal of Medicine, 2006
- Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast CancerJournal of Clinical Oncology, 2006
- The apoptotic action of estrogen following exhaustive antihormonal therapy: A new clinical treatment strategyThe Breast, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Performance evaluation of the whole-body PET scanner ECAT EXACT HR/sup +/ following the IEC standardIEEE Transactions on Nuclear Science, 1997
- 13C NMR kinetic studies of the rapid stimulation of glucose metabolism by estrogen in immature rat uterusNMR in Biomedicine, 1994
- Local threshold for segmented attenuation correction of PET imaging of the thoraxIEEE Transactions on Nuclear Science, 1994
- The ECAT EXACT HRJournal of Computer Assisted Tomography, 1994
- Tamoxifen induced changes in MCF7 human breast cancer: In vitro and in vivo studies using nuclear magnetic resonance spectroscopy and imagingThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- Performance Evaluation of the Positron Scanner ECAT EXACTJournal of Computer Assisted Tomography, 1992